
A group of undisclosed business angels also participated in the round.
The company, which has developed an innovative platform (comprising machines, chips, software and reagents) for the extraction and analysis of rare cells, based on the principle of dielectrophoresis, will use the capital infusion to continue development activities, clinical testing of medical applications, and to expand abroad.
In conjuntion with the financing, Aurelio Mezzotero, Investment Director of Atlante Ventures, and Fabrizio Landi, Managing Director and General Manager of Esaote, will join Silicon Biosystems’ board of directors.
FinSMEs
18/03/2010